A Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy of Xolair in an Allergen Bronchoprovocation Study in Asthmatic Populations Defined by Serum IgE Concentrations.
Phase of Trial: Phase IV
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2017 Results of omalizumab against early and late allergic responses after four weeks (n=10) published in the Allergy
- 11 Feb 2011 Trial phase changed from II to IV as reported by ClinicalTrials.gov.